GV and Novartis Venture Fund joined 6 Dimensions Capital in a round that brought the oncology drug developer's overall funding to $160m.
US-based T-cell receptor therapy developer TScan Therapeutics closed a $100m series C round yesterday featuring internet and technology group Alphabet’s GV subsidiary and Novartis Venture Fund, part of pharmaceutical firm Novartis.
The round included 6 Dimensions Capital, the biotech investment firm co-founded by a subsidiary of pharmaceutical firm WuXi AppTec, as well as Longwood Fund, Bessemer Venture Partners (BVP) and Pitango Venture Capital (through subsidiary Pitango HealthTech).
RA Capital Management filled out the round with funds and accounts managed by…
